IP Library › Granted Patent US 11,155,583
Granted Patent B2
US 11,155,583 · App. 16/091,344 · Granted Oct 26, 2021

Stabilized soluble pre-fusion RSV F proteins

Inventors: Anders Krarup (Glostrup, DK); Johannes Petrus Maria Langedijk (Amsterdam, NL)
Assignee: Janssen Vaccines & Prevention B.V.
C07K14/135A61K39/12A61P31/14C07K14/005C07K16/1027C12N15/62A61K2039/55505A61K2039/57C12N2760/18522C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,583
App. No.
16/091,344
Granted
Oct 26, 2021
Kind
B2
Abstract

Stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.

Claims (19)

1. A nucleic acid molecule encoding a recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) protein, the nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

2. The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 20.

3. A vector comprising the nucleic acid molecule according to claim 2 .

4. A composition comprising the nucleic acid molecule according to claim 2 .

5. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 4 .

6. A method of prophylaxis and/or treatment of RSV infection in a subject in need thereof, the method comprising administering to the subject the composition according to claim 4 .

7. A vaccine against RSV comprising the nucleic acid molecule according to claim 2 .

8. The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 21.

9. A vector comprising the nucleic acid molecule according to claim 8 .

10. A composition comprising the nucleic acid molecule according to claim 8 .

11. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 10 .

12. A method of prophylaxis and/or treatment of RSV infection in a subject in need thereof, the method comprising administering to the subject the composition according to claim 10 .

13. A vaccine against RSV comprising the nucleic acid molecule according to claim 8 .

14. The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 22.

15. A vector comprising the nucleic acid molecule according to claim 14 .

16. A composition comprising the nucleic acid molecule according to claim 14 .

17. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 16 .

18. A method of prophylaxis and/or treatment of RSV infection in a subject in need thereof, the method comprising administering to the subject the composition according to claim 16 .

19. A vaccine against RSV comprising the nucleic acid molecule according to claim 14 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2018
From: KRARUP, ANDERS; LANGEDIJK, JOHANNES PETRUS MARIA
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 047070/0803 →
Priority Claims (1)
EP 16163810 · Apr 5, 2016 · regional
Continuity (1)
Related Publication 20190119330A1 · Apr 25, 2019
Cited By (2)
US 12,234,264 US 12,331,077